Top Ten most popular articles on Pharmafile.com this week
The past week in the industry has brought much hope for patients with the news of significant research data developments in cancer, along with a range of new treatment approvals and even NICE's announcement that 14 drugs previously only available through the Cancer Drugs Fund are now routinely available on the NHS.
The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients of the disease in twelve years.
Aranca discusses the considerable advances that have occurred in the last few years in gene therapy.
Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. The study was held over a duration of 52 weeks, with Taltz displaying high proportion of response from patients.
NICE has approved the transferral of 14 drugs across 18 indications from the Cancer Drugs Fund to routine use across the NHS.
Research has identified that the function of metabolic enzyme AKR1B1 is key to the progression of aggressive ‘basal-like’ breast cancer, meaning an existing diabetes drug which inhibits it may be useful in fighting the disease.
Ben Hargreaves looks at the pricing debate occurring within Europe and how it could lead to closer relations between countries within the EU.
Phase 3 data for the human monoclonal antibody guselkumab in the treatment of adults with moderate to severe plaque psoriasis, showed significant efficacy compared to Abbvie’s blockbuster drug Humira.
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and psoriatic, were invalid. The case was brought by claimants Samsung Bioepis, Biogen and Fujifilm Kyowa Kirin Biologics.
Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from scientists at Imperial College London has found.
AstraZeneca has announced that its type-2 diabetes treatment Qtern (10mg dapagliflozin and 5mg saxagliptin) has received the approval of the US Food and Drug Administration.